Navigation Links
Simeprevir Administered Once Daily as Part of Combination Therapy Demonstrates Sustained Virologic Response in Treatment-Naive and Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients
Date:11/2/2013

f the other Janssen Pharmaceutical Companies and/or Johnson & Johnson.  Risks and uncertainties include, but are not limited to, general industry conditions and competition; economic factors, such as interest rate and currency exchange rate fluctuations; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approvals; challenges to patents; impact of business combinations; changes in behavior and spending patterns or financial distress of purchasers of health care products and services; changes to governmental laws and regulations and domestic and foreign health care reforms; trends toward health care cost containment; and increased scrutiny of the health care industry by government agencies.  A further list and description of these risks, uncertainties and other factors can be found in Exhibit 99 of Johnson & Johnson's Annual Report on Form 10-K for the fiscal year ended December 30, 2012.  Copies of this Form 10-K, as well as subsequent filings, are available online at www.sec.gov, www.jnj.com or on request from Johnson & Johnson.  None of the Janssen Pharmaceutical Companies nor Johnson & Johnson undertake to update any forward-looking statements as a result of new information or future events or developments.)

Media Contact: Daniel De Schryver               
Mobile: +49 173 76 89 149

Media Contact: Craig Stoltz               
Mobile: +1 (215) 325-3612

Investor Contact: Stan Panasewicz                      
Off
'/>"/>

SOURCE Janssen R&D Ireland
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Simeprevir Data in Hepatitis C Patients to be Presented at the Annual Meeting of the American Association for the Study of Liver Diseases (AASLD)
2. Primary Efficacy and Safety Findings from Phase 3 Study of Janssens Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients
3. U.S. FDA Grants Priority Review to Simeprevir (TMC435) for Combination Treatment of Genotype 1 Chronic Hepatitis C
4. Janssen and Johnson & Johnson to Provide Webcast Presentation of Simeprevir Phase 3 Clinical Data Presented at The International Liver Congress of the European Association for the Study of the Liver (EASL)
5. Findings from Two Phase 3 Studies of Janssens Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Genotype 1 Chronic Hepatitis C Patients
6. Janssen Submits New Drug Application to U.S. FDA for Simeprevir (TMC435) for Combination Treatment of Adult Patients with Genotype 1 Chronic Hepatitis C
7. Efficacy and Safety Data from Phase 2B Trials of Janssens Simeprevir in Hepatitis C Patients with Advanced Fibrosis of the Liver Presented at Annual Meeting of the American Association for the Study of Liver Diseases
8. Janssen Announces Collaboration with Vertex on Phase 2 Study to Investigate an All-Oral Regimen of Simeprevir (TMC435) and VX-135 for Treatment of Hepatitis C
9. MCOs Shifting Control Over Office-Administered Products from Medical to Pharmacy Benefit, Particularly Affecting Rheumatoid Arthritis Therapies
10. American Journal of Medicine Publishes Hypertension Study Comparing the Fixed-Dose Combination of Azilsartan Medoxomil and Chlorthalidone versus Azilsartan Medoxomil Co-administered with Hydrochlorothiazide
11. Daiichi Sankyos Once-Daily Edoxaban Shows Comparable Efficacy and Superiority for the Principal Safety Endpoint Compared to Warfarin in a Phase 3 Study for the Treatment of Symptomatic VTE and Prevention of its Recurrence
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/24/2015)... , April 24, 2015  Lannett Company, Inc. (NYSE: ... and increased its five-year revolving credit facility to $120 ... accordion feature that will allow the company to increase ... $30.0 million, subject to securing additional commitments from existing ... the credit facility remains December 18, 2018.   ...
(Date:4/24/2015)... 2015 Hospira, Inc. (NYSE: ... biosimilar therapies, spoke about the importance of extrapolation in ... Association (EGA) annual European Biosimilars Group conference in ... announced the publication of a pivotal white paper titled, ... promise of biosimilars." Speaking at the ...
(Date:4/24/2015)... April 24, 2015  Blueprint Medicines today announced ... and potent inhibitor of fibroblast growth factor receptor ... of hepatocellular carcinoma (HCC) that are dependent on ... induced complete tumor regression in a subset of ... at the highest dose levels. These data will ...
Breaking Medicine Technology:Lannett Expands Revolving Credit Facility To $120 Million 2Hospira Leadership Presents at Preeminent European Biosimilars Forum, Announces New White Paper on Extrapolation 2Hospira Leadership Presents at Preeminent European Biosimilars Forum, Announces New White Paper on Extrapolation 3Hospira Leadership Presents at Preeminent European Biosimilars Forum, Announces New White Paper on Extrapolation 4Hospira Leadership Presents at Preeminent European Biosimilars Forum, Announces New White Paper on Extrapolation 5Hospira Leadership Presents at Preeminent European Biosimilars Forum, Announces New White Paper on Extrapolation 6Hospira Leadership Presents at Preeminent European Biosimilars Forum, Announces New White Paper on Extrapolation 7Blueprint Medicines Presents New Preclinical Data Demonstrating Its Drug Candidate BLU-554 Induces Significant Tumor Regression in Models of Hepatocellular Carcinoma 2Blueprint Medicines Presents New Preclinical Data Demonstrating Its Drug Candidate BLU-554 Induces Significant Tumor Regression in Models of Hepatocellular Carcinoma 3
... for TREANDA by End of ... ... today announced positive results from a Phase 3 clinical trial of,TREANDA(R) (bendamustine ... responsive to treatment with,rituximab. The study met its primary endpoints of overall ...
... Advance SNS-595 to Next Stage of Phase 2 ... 23 /ADVANCE,FOR RELEASE AT 3:30 P.M. EDT, ... a clinical-stage biopharmaceutical company developing novel,anticancer therapeutics, today ... the company,s ongoing Phase 2 clinical trial of ...
Cached Medicine Technology:Cephalon Announces Positive Results from Its Pivotal Study of TREANDA in Patients with Non-Hodgkin's Lymphoma 2Cephalon Announces Positive Results from Its Pivotal Study of TREANDA in Patients with Non-Hodgkin's Lymphoma 3Cephalon Announces Positive Results from Its Pivotal Study of TREANDA in Patients with Non-Hodgkin's Lymphoma 4Sunesis Pharmaceuticals Reports Preliminary SNS-595 Activity in Ovarian Cancer Clinical Trial at AACR-NCI-EORTC International Conference 2Sunesis Pharmaceuticals Reports Preliminary SNS-595 Activity in Ovarian Cancer Clinical Trial at AACR-NCI-EORTC International Conference 3Sunesis Pharmaceuticals Reports Preliminary SNS-595 Activity in Ovarian Cancer Clinical Trial at AACR-NCI-EORTC International Conference 4Sunesis Pharmaceuticals Reports Preliminary SNS-595 Activity in Ovarian Cancer Clinical Trial at AACR-NCI-EORTC International Conference 5
(Date:4/25/2015)... Providenciales, Turks and Caicos Islands, BWI (PRWEB) April 25, ... Providenciales International Airport (PLS) has celebrated three months of ... since reopening on January 5, 2015. , As ... phases, the interior of Providenciales airport was completely redesigned ... area has quickened up the process of getting out ...
(Date:4/25/2015)... April 25, 2015 On Friday, April ... RFID Journal’s annual Best Implementation Award. This award ... the best use of RFID technology to improve its ... the company that best demonstrates how RFID is delivering ... at RFID Journal Live! 2015 in San Diego, the ...
(Date:4/24/2015)... AK (PRWEB) April 24, 2015 As ... (#MOTMC2015) and the unique sacrifices of these young men ... for Service members, Veterans and their Families” presents a ... training is designed to gain a better understanding of ... health and wellness. For those – civilian and military ...
(Date:4/24/2015)... The 1975 have had an intense ... globe to theaters, festivals and TV performances. Now that they’ve ... their label, Dirty Hit Records, to provide clean drinking water ... launched Cadence & Cause website, this four-piece has ... and a signed photo card. Entries from this sweepstakes ...
(Date:4/24/2015)... Anchor Health Administrators (Anchor), specialists in Long-Term ... their exclusive agreement with LTC Solutions for All LLC ... partner. , Anchor has more than 18 years of ... associations, and is currently the designated advocate for the ... Insurance member benefit. , “I am very pleased to ...
Breaking Medicine News(10 mins):Health News:The Tuscany on Grace Bay Celebrates Providenciales Airport Expansion With Summer Specials to Travelers! 2Health News:Seeonic’s Industry Leading Technology Powers Interstate Batteries to Winning Award 2Health News:Coalition Presents Resiliency Training to Raise Awareness during Month of the Military Child (#MOTMC2015) 2Health News:Internationally Recognized British Indie Rock Outfit The 1975 Partner with Cadence & Cause to Provide Clean Drinking Water to Those in Need 2
... simulation exhibition event ever held will feature top leaders from ... opening ceremonies of the Interservice/Industry Training, Simulation and Education Conference ... Army Training and Doctrine Command (TRADOC). Joining him will ... Martin Joint Strike Fighter Program. , ...
... Latina women who prefer speaking Spanish are more likely ... with their breast cancer treatment, according to a new ... Cancer Center. , Despite receiving similar treatment, Latina women ... report high levels of dissatisfaction and regret about their ...
... and healthcare information resource, today released the results ... increasing healthcare costs and more infrequent doctor visits. ... percent) indicated they are going to the doctor ... healthcare costs. In an additional question of 274 ...
... when given before birth, glucocorticoids tied to cognitive, motor ... News) -- Glucocorticoid drugs used to treat chronic lung ... and may cause cognitive and motor control problems even ... Washington University School of Medicine in St. Louis. , ...
... found little link between drinking and malignancies , , MONDAY, ... your chances of developing cancer after age 65, new ... lack of physical activity were among the usual suspects ... to the Duke University study. , The findings are ...
... a test would be especially useful for blacks, other high-risk ... someday be able to use five genetic markers to assess ... cancer, a new study suggests. , If reliable, these five ... patients, or men of any race with a family history ...
Cached Medicine News:Health News:Military, Industry Leaders to Speak at World's Largest Simulation Event 2Health News:Military, Industry Leaders to Speak at World's Largest Simulation Event 3Health News: More Than Half of Consumers Going to Doctors Less Due to Rising Healthcare Costs, According to checkMD Survey : 38 Percent Lack Adequate Employer Healthcare Coverage 2Health News: More Than Half of Consumers Going to Doctors Less Due to Rising Healthcare Costs, According to checkMD Survey : 38 Percent Lack Adequate Employer Healthcare Coverage 3Health News:Drugs to Treat Lung Damage in Preemies May Harm Brain 2Health News:Stay Upbeat, Exercise to Help Prevent Cancer in Old Age 2Health News:Gene Screen Might Predict Prostate Cancer 2
... Recently updated with a high ... the new Kowa Non Myd - ... quality, style and ease of use. ... comprehensive, easy to install VK-2 image ...
The quick access to diabetic screening, panoramic images of the retina including peripheral area are available by using easy, semi automatic guidance of peripheral fixation....
Measurement of progressive multi-focal lenses is fast and easy with the CLM-3100P auto-lensmeter. The data is represented in a simple to understand graphic display....
Autolensmeter with color 5.7 inch LCD screen and built in printer....
Medicine Products: